<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03502707</url>
  </required_header>
  <id_info>
    <org_study_id>CR108456</org_study_id>
    <secondary_id>VAC18193RSV1004</secondary_id>
    <nct_id>NCT03502707</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety and Concomitant Influenza Vaccine Administration in Adults Aged 60 Years and Older</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety and Concomitant Influenza Vaccine Administration in Adults Aged 60 Years and Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Vaccines &amp; Prevention B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Vaccines &amp; Prevention B.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study for:

      Cohort 1 and Cohort 2: to assess the safety and reactogenicity of the intramuscular one- and
      two-dose regimens, with a booster at Month 12 and to select a regimen for Cohort 3.

      Cohort 2 and part of Cohort 1: to assess respiratory syncytial virus (RSV) neutralizing
      antibody levels of all regimens containing RSV pre-fusion (preF) protein compared to the
      one-dose adenovirus serotype 26 respiratory syncytial virus pre-fusion (Ad26.RSV.preF)
      regimen.

      Cohort 3: to demonstrate the non-inferiority of the concomitant administration of the
      selected regimen and seasonal influenza vaccine versus the administration of seasonal
      influenza vaccine alone in terms of humoral immune response expressed by the geometric mean
      titers (GMTs) of hemagglutination inhibition (HI) antibody titers against the influenza
      vaccine strains 28 days after the administration of influenza vaccine, using a
      non-inferiority margin of 2 for the GMT ratio (control group/co-administration group) and to
      assess the safety and reactogenicity of the selected regimen administered separately or
      concomitantly with seasonal influenza vaccine, and a booster at Month 12, and to compare the
      safety and reactogenicity of the co-administration group with that of the seasonal influenza
      vaccine + placebo group.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">February 5, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 22, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cohorts 1 and 2: Number of Participants With Serious Adverse Events (SAEs)</measure>
    <time_frame>From Day 1 until the End of Study (up to 2 years)</time_frame>
    <description>An SAE is an adverse event (AE) resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 3: Number of Participants With SAEs</measure>
    <time_frame>From the initial Fluarix/placebo vaccination (at least 14 days prior to Day 1) until the End of Study (up to 2 years)</time_frame>
    <description>An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohorts 1 and 2: Number of Participants With Solicited Local and Systemic AEs for 7 Days After Each Vaccination</measure>
    <time_frame>From Day 1 until 7 days after each vaccination (up to Day 372)</time_frame>
    <description>Solicited AEs are pre-defined local (at the injection site) and systemic events for which participants are specifically questioned and which are noted by participants in their diary. Solicited local AEs: pain/tenderness, induration/swelling and erythema. Solicited systemic AEs: fever, fatigue, headache, myalgia, arthralgia, chills, and nausea. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 3: Number of Participants With Solicited Local and Systemic AEs for 7 Days After Each Vaccination</measure>
    <time_frame>From the initial Fluarix/placebo vaccination (at least 14 days prior to Day 1) until 7 days after each vaccination (up to Day 372)</time_frame>
    <description>Solicited AEs are pre-defined local (at the injection site) and systemic events for which participants are specifically questioned and which are noted by participants in their diary. Solicited local AEs: pain/tenderness, induration/swelling and erythema. Solicited systemic AEs: fever, fatigue, headache, myalgia, arthralgia, chills, and nausea. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohorts 1 and 2: Number of Participants With Unsolicited AEs for 28 Days After Each Vaccination</measure>
    <time_frame>From Day 1 until 28 days after each vaccination (up to Day 393)</time_frame>
    <description>Unsolicited AEs are all AEs for which participants are specifically not questioned in the participant diary. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 3: Number of Participants With Unsolicited AEs for 28 Days After Each Vaccination</measure>
    <time_frame>From the initial Fluarix/placebo vaccination (at least 14 days prior to Day 1) until 28 days after each vaccination (up to Day 393)</time_frame>
    <description>Unsolicited AEs are all AEs for which participants are specifically not questioned in the participant diary. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 2: Respiratory Syncytial Virus (RSV) A2 Neutralizing Antibody Levels of the 1-Dose Regimen</measure>
    <time_frame>Day 29</time_frame>
    <description>Analysis of RSV A2 neutralizing antibody levels of the vaccine-induced immune response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 2: RSV A2 Neutralizing Antibody Levels of the 2-Dose Regimen</measure>
    <time_frame>Day 85</time_frame>
    <description>Analysis of RSV A2 neutralizing antibody levels of the vaccine-induced immune response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 3: Hemagglutination Inhibition (HI) Antibody Titers Against the Influenza Vaccine Strains</measure>
    <time_frame>28 days after Fluarix/placebo vaccination (Day 14 [for participants with vaccination at Day -14])</time_frame>
    <description>Humoral immune responses expressed by the geometric mean titers (GMTs) of HI antibody titers 28 days after the seasonal influenza vaccination between the seasonal influenza vaccine alone and co-administered groups for each of the 4 seasonal influenza vaccine strains.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 3: Hemagglutination Inhibition (HI) Antibody Titers Against the Influenza Vaccine Strains</measure>
    <time_frame>28 days after Fluarix/placebo vaccination (Day 28 [for participants with vaccination at Day 1])</time_frame>
    <description>Humoral immune responses expressed by the geometric mean titers (GMTs) of HI antibody titers 28 days after the seasonal influenza vaccination between the seasonal influenza vaccine alone and co-administered groups for each of the 4 seasonal influenza vaccine strains.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cohorts 1 and 2: Respiratory Syncytial Virus (RSV) Neutralization Assays</measure>
    <time_frame>At Day 1 (1st vaccination), Day 15, 29, 57 (2nd vaccination), Day 85, 183, 365 (3rd vaccination), Day 393, 547, 730 or Early Exit (up to 2 years)</time_frame>
    <description>Analysis of neutralizing antibodies to RSV will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts 1 and 2: RSV Fusion Protein (F Protein) Binding Antibodies (Enzyme-Linked Immunosorbent Assay [ELISA]; Pre-Fusion [Pre-F] and/or Post-Fusion [Post-F])</measure>
    <time_frame>At Day 1 (1st vaccination), Day 15, 29, 57 (2nd vaccination), Day 85, 183, 365 (3rd vaccination), Day 393, 547, 730 or Early Exit (up to 2 years)</time_frame>
    <description>Analysis of antibodies binding to RSV F protein in post-fusion (stable conformation) and pre-fusion (metastable conformation) form will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts 1 and 2: Interferon Gamma (IFN-γ) Enzyme-Linked Immunospot (ELISpot) Assay</measure>
    <time_frame>At Day 1 (1st vaccination), Day 15, 29, 57 (2nd vaccination), Day 85, 183, 365 (3rd vaccination), Day 393, 547, 730 or Early Exit (up to 2 years)</time_frame>
    <description>IFN-γ ELISpot assay to assess the RSV F-specific cellular immune responses elicited by the different vaccine regimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 3: RSV Neutralization A2 Strain</measure>
    <time_frame>Day 29 (for 1-dose regimen) and Day 85 (for 2-dose regimen)</time_frame>
    <description>Analysis of RSV A2 neutralizing antibody titers of the vaccine-induced immune response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 3: IFN-γ ELISpot Assay</measure>
    <time_frame>Day 29 (for 1-dose regimen) and Day 85 (for 2-dose regimen)</time_frame>
    <description>IFN-γ ELISpot assay to assess the RSV F-specific cellular immune responses elicited by the selected vaccine regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 3: Fold Rise From Baseline in HI Antibody Titers Against the Seasonal Influenza Vaccine Strains</measure>
    <time_frame>Baseline, 28 days after Fluarix/placebo vaccination (Day 14 [for participants with vaccination at Day -14] and Day 28 [for subjects with vaccination at Day 1])</time_frame>
    <description>Fold rise from baseline in HI antibody titers against the seasonal influenza vaccine strains, 28 days after seasonal influenza vaccine administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 3: Percentage of Participants with Post-Vaccination HI Antibody Titers &gt;=1:40 in Participants with a Pre Vaccination Titer of &lt;1:10, or a &gt;=4-Fold Titer Increase in Participants with a Pre-Vaccination Titer of &gt;=1:10</measure>
    <time_frame>28 days after Fluarix/placebo vaccination (Day 14 [for participants with vaccination at Day -14] and Day 28 [for subjects with vaccination at Day 1])</time_frame>
    <description>Percentage of participants with post-vaccination HI antibody titers greater than or equal to (&gt;=) 1:40 in participants with a pre vaccination titer of less than (&lt;) 1:10, or a &gt;=4-fold titer increase in participants with a pre-vaccination titer of &gt;=1:10 will be evaluated to assess seroconversion rates against the influenza vaccine strains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 3: Percentage of Participants with a Post-Vaccination HI Antibody Titers &gt;=1:40</measure>
    <time_frame>28 days after Fluarix/placebo vaccination (Day 14 [for participants with vaccination at Day -14] and Day 28 [for subjects with vaccination at Day 1])</time_frame>
    <description>Percentage of participants with a post-vaccination HI antibody titers &gt;=1:40 will be evaluated to assess seroprotection rates against the influenza vaccine strains.</description>
  </secondary_outcome>
  <number_of_arms>23</number_of_arms>
  <enrollment type="Anticipated">562</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort (C)1 Group (G)1: Placebo for RSV preF Protein</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive intramuscular injection of placebo on Day 1, Day 57 and at Month 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C1 G2: RSV preF Protein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intramuscular injection of 50 microgram (mcg) RSV preF protein on Day 1, Day 57 and at Month 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C1 G3: Placebo for Ad26.RSV.preF/RSV preF or RSV preF Protein</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive intramuscular injection of placebo on Day 1, Day 57 and at Month 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C1 G4: Mixture of Ad26.RSV.preF/RSV preF Protein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intramuscular injection of a mixture of 5*10^10 viral particles (vp) of Ad26.RSV.preF/RSV preF 50 mcg protein on Day 1, Day 57 and at Month 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C1 G5: RSV preF Protein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intramuscular injection of 150 mcg RSV preF protein on Day 1, Day 57 and at Month 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C1 G6: Mixture of Placebo for Ad26.RSV.preF/RSV preF Protein</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive intramuscular injection of placebo on Day 1, Day 57 and at Month 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C1 G7: Mixture of Ad26.RSV.preF/RSV preF Protein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intramuscular injection of a mixture of 5*10^10 vp of Ad26.RSV.preF plus 150 mcg RSV preF protein on Day 1, Day 57 and at Month 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C1 G8: Placebo for Ad26.RSV.preF/Placebo for RSV preF Protein</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive intramuscular injection of placebo on Day 1 and at Month 12 and in only 1 arm on Day 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C1 G9: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intramuscular injection of a mixture of 1*10^11 vp of Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm on Day 1 and 57 and at Month 12 and placebo in another arm on Day 1 and at Month 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C1 G10: Ad26.RSV.preF, RSV preF Protein and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intramuscular injection of 1*10^11 vp of Ad26.RSV.preF in 1 Arm and 150 mcg RSV preF protein in another arm on Day 1 and at Month 12 and placebo in 1 arm on Day 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C2 G11: Ad26.RSV.preF and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intramuscular injection of 1*10^11 vp of Ad26.RSV.preF in 1 arm and placebo in another arm on Day 1 and at Month 12 and placebo in 1 arm on Day 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C2 G12: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intramuscular injection of a mixture of 5*10^10 vp Ad26.RSV.preF plus 50 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and at Month 12 and placebo in 1 arm on Day 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C2 G13: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intramuscular injection of a mixture of 1*10^11 vp Ad26.RSV.preF plus 50 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and at Month 12 and placebo in 1 arm on Day 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C2 G14: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intramuscular injection of a mixture of 1*10^11 vp Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and at Month 12 and placebo in 1 arm on Day 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C2 G15: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intramuscular injection of a mixture of 5*10^10 vp Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and at Month 12 and placebo in 1 arm on Day 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C2 G16: Ad26.RSV.preF, RSV preF Protein and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Data from C1 G10 will be pooled with those of C2 G16. Participants will receive intramuscular injection of 1*10^11 vp of Ad26.RSV.preF in 1 Arm and 150 mcg RSV preF protein in another arm on Day 1 and at Month 12 and placebo in 1 arm on Day 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C2 G17: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Data from C1 G9 will be pooled with those of C2 G17. Participants will receive intramuscular injection of a mixture of 1*10^11 vp of Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm on Day 1 and 57 and at Month 12 and placebo in another arm on Day 1 and at Month 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C2 G18: Placebo for Ad26.RSV.preF/Placebo for RSV preF Protein</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive intramuscular injection of placebo in separate arms on Day 1 and at Month 12 and in only 1 arm on Day 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C3 G19: Fluarix Placebo, Selected Regimen (SR) + Fluarix, SR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants assigned to one-dose regimen in this group will receive intramuscular injection of placebo for seasonal influenza vaccine (Fluarix) at least 14 days prior to Day 1 followed by selected regimen in 1 arm and Fluarix in another arm on Day 1 followed by selected regimen at Month 12, for one-dose regimen. The participants who are randomized to two-dose regimen will receive an additional intramuscular injection of selected regimen on Day 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C3 G20: Fluarix, SR + Fluarix Placebo, SR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants assigned to one-dose regimen in this group will receive intramuscular injection of Fluarix at least 14 days prior to Day 1 followed by selected regimen in 1 arm and placebo for Fluarix in another arm on Day 1 followed by selected regimen at Month 12, for one-dose regimen. The participants who are randomized to two-dose regimen will receive an additional intramuscular injection of selected regimen on Day 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C3 G21: Fluarix Placebo, SR + Fluarix, SR Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants assigned to one-dose regimen in this group will receive intramuscular injection of placebo for Fluarix at least 14 days prior to Day 1 followed by selected regimen in 1 arm and Fluarix in another arm on Day 1 followed by placebo for selected regimen at Month 12, for one-dose regimen. The participants who are randomized to two-dose regimen will receive an additional intramuscular injection of selected regimen on Day 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C3 G22: Fluarix, SR + Fluarix Placebo, SR Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants assigned to one-dose regimen in this group will receive intramuscular injection of Fluarix at least 14 days prior to Day 1 followed by selected regimen in 1 arm and placebo for Fluarix in another arm on Day 1 followed by placebo for selected regimen at Month 12, for one-dose regimen. The participants who are randomized to two-dose regimen will receive an additional intramuscular injection of selected regimen on Day 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C3 G23: Fluarix, SR Placebo + Fluarix Placebo, SR Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants assigned to one-dose regimen in this group will receive intramuscular injection of Fluarix at least 14 days prior to Day 1 followed by placebo for selected regimen in 1 arm and placebo for Fluarix in another arm on Day 1 followed by placebo for selected regimen at Month 12, for one-dose regimen. The participants who are randomized to two-dose regimen will receive an additional intramuscular injection of placebo for selected regimen on Day 57.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for Ad26.RSV.preF, RSV preF protein, Ad26.RSV.preF/RSV preF Protein Mixture, selected regimen, and seasonal influenza vaccine will be administered as sterile saline for intramuscular injection.</description>
    <arm_group_label>Cohort (C)1 Group (G)1: Placebo for RSV preF Protein</arm_group_label>
    <arm_group_label>C1 G3: Placebo for Ad26.RSV.preF/RSV preF or RSV preF Protein</arm_group_label>
    <arm_group_label>C1 G6: Mixture of Placebo for Ad26.RSV.preF/RSV preF Protein</arm_group_label>
    <arm_group_label>C1 G8: Placebo for Ad26.RSV.preF/Placebo for RSV preF Protein</arm_group_label>
    <arm_group_label>C1 G9: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
    <arm_group_label>C1 G10: Ad26.RSV.preF, RSV preF Protein and Placebo</arm_group_label>
    <arm_group_label>C2 G11: Ad26.RSV.preF and Placebo</arm_group_label>
    <arm_group_label>C2 G12: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
    <arm_group_label>C2 G13: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
    <arm_group_label>C2 G14: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
    <arm_group_label>C2 G15: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
    <arm_group_label>C2 G16: Ad26.RSV.preF, RSV preF Protein and Placebo</arm_group_label>
    <arm_group_label>C2 G17: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
    <arm_group_label>C2 G18: Placebo for Ad26.RSV.preF/Placebo for RSV preF Protein</arm_group_label>
    <arm_group_label>C3 G19: Fluarix Placebo, Selected Regimen (SR) + Fluarix, SR</arm_group_label>
    <arm_group_label>C3 G20: Fluarix, SR + Fluarix Placebo, SR</arm_group_label>
    <arm_group_label>C3 G21: Fluarix Placebo, SR + Fluarix, SR Placebo</arm_group_label>
    <arm_group_label>C3 G22: Fluarix, SR + Fluarix Placebo, SR Placebo</arm_group_label>
    <arm_group_label>C3 G23: Fluarix, SR Placebo + Fluarix Placebo, SR Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RSV preF Protein 50 mcg</intervention_name>
    <description>RSV preF will be administered as a solution for intramuscular injection at a dose of 50 mcg.</description>
    <arm_group_label>C1 G2: RSV preF Protein</arm_group_label>
    <other_name>JNJ-64213175</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RSV preF Protein 150 mcg</intervention_name>
    <description>RSV preF will be administered as a solution for intramuscular injection at a dose of 150 mcg.</description>
    <arm_group_label>C1 G5: RSV preF Protein</arm_group_label>
    <arm_group_label>C1 G10: Ad26.RSV.preF, RSV preF Protein and Placebo</arm_group_label>
    <arm_group_label>C2 G16: Ad26.RSV.preF, RSV preF Protein and Placebo</arm_group_label>
    <other_name>JNJ-64213175</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad26.RSV.preF 1*10^11 vp</intervention_name>
    <description>Ad26.RSV.preF will be administered as a solution for intramuscular injection at a dose of 1*10^11 vp.</description>
    <arm_group_label>C1 G10: Ad26.RSV.preF, RSV preF Protein and Placebo</arm_group_label>
    <arm_group_label>C2 G11: Ad26.RSV.preF and Placebo</arm_group_label>
    <arm_group_label>C2 G16: Ad26.RSV.preF, RSV preF Protein and Placebo</arm_group_label>
    <other_name>JNJ-64400141</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 50 mcg</intervention_name>
    <description>Mixture of Ad26.RSV.preF (5*10^10 vp) and RSV preF protein (50 mcg) will be administered as a solution for intramuscular injection.</description>
    <arm_group_label>C1 G4: Mixture of Ad26.RSV.preF/RSV preF Protein</arm_group_label>
    <arm_group_label>C2 G12: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 150 mcg</intervention_name>
    <description>Mixture of Ad26.RSV.preF (5*10^10 vp) and RSV preF protein (150 mcg) will be administered as a solution for intramuscular injection.</description>
    <arm_group_label>C1 G7: Mixture of Ad26.RSV.preF/RSV preF Protein</arm_group_label>
    <arm_group_label>C2 G15: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 50 mcg</intervention_name>
    <description>Mixture of Ad26.RSV.preF (1*10^11 vp) and RSV preF protein (50 mcg) will be administered as a solution for intramuscular injection.</description>
    <arm_group_label>C2 G13: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 150 mcg</intervention_name>
    <description>Mixture of Ad26.RSV.preF (1*10^11 vp) and RSV preF protein (150 mcg) will be administered as a solution for intramuscular injection.</description>
    <arm_group_label>C1 G9: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
    <arm_group_label>C2 G14: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
    <arm_group_label>C2 G17: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Seasonal Influenza Vaccine (Fluarix)</intervention_name>
    <description>Fluarix will be administered as a suspension containing 4 strains of influenza viruses with 15 mcg of hemagglutinin (HA) for each strain per 0.5 milliliter (mL) for intramuscular injection.</description>
    <arm_group_label>C3 G19: Fluarix Placebo, Selected Regimen (SR) + Fluarix, SR</arm_group_label>
    <arm_group_label>C3 G20: Fluarix, SR + Fluarix Placebo, SR</arm_group_label>
    <arm_group_label>C3 G21: Fluarix Placebo, SR + Fluarix, SR Placebo</arm_group_label>
    <arm_group_label>C3 G22: Fluarix, SR + Fluarix Placebo, SR Placebo</arm_group_label>
    <arm_group_label>C3 G23: Fluarix, SR Placebo + Fluarix Placebo, SR Placebo</arm_group_label>
    <other_name>Fluarix Quadrivalent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Selected Regimen</intervention_name>
    <description>A regimen from Cohort 1 or Cohort 2 will be selected and administered as a solution for intramuscular injection at the selected dose.</description>
    <arm_group_label>C3 G19: Fluarix Placebo, Selected Regimen (SR) + Fluarix, SR</arm_group_label>
    <arm_group_label>C3 G20: Fluarix, SR + Fluarix Placebo, SR</arm_group_label>
    <arm_group_label>C3 G21: Fluarix Placebo, SR + Fluarix, SR Placebo</arm_group_label>
    <arm_group_label>C3 G22: Fluarix, SR + Fluarix Placebo, SR Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Before randomization, a woman must be postmenopausal (postmenopausal state is defined
             as no menses for 12 months without an alternative medical cause) and not intending to
             conceive by any methods

          -  In the investigator's clinical judgment, participant must be either in good or stable
             health. Participants may have underlying illnesses such as hypertension, type 2
             diabetes mellitus, hyperlipoproteinemia, or hypothyroidism, as long as their symptoms
             and signs are medically controlled. If they are on medication for a condition, the
             medication dose must have been stable for at least 12 weeks preceding vaccination and
             expected to remain stable for the duration of the study. Participants will be included
             on the basis of physical examination, medical history, vital signs, and 12-lead
             electrocardiogram (ECG) performed at screening

          -  For participants in Cohorts 1 and 2 only: Participant must be healthy on the basis of
             clinical laboratory tests performed at screening. If the results of the laboratory
             screening tests are outside the central laboratory normal reference ranges and
             additionally within the limits of toxicity Grade 2 according to the United States (US)
             Food and Drug Administration (FDA) toxicity, the participant may be included only if
             the investigator judges the abnormalities or deviations from normal to be not
             clinically significant and appropriate and reasonable for the population under study.
             This determination must be recorded in the participant's source documents and
             initialed by the investigator

          -  From the time of each vaccination through 3 months after each vaccination, participant
             agrees not to donate blood

          -  Participant must be willing to provide verifiable identification, have means to be
             contacted and to contact the investigator during the study

        Exclusion Criteria:

          -  Per serology testing in Cohorts 1 and 2 and per medical history in Cohort 3:
             Participant has chronic active hepatitis B or hepatitis C infection, documented by
             hepatitis B surface antigen and hepatitis C antibody, respectively

          -  Per serology testing in Cohorts 1 and 2 and per medical history in Cohort 3:
             Participant has human immunodeficiency virus (HIV) type 1 or type 2 infection

          -  Participant has had major psychiatric illness and/or drug or alcohol abuse which in
             the investigator's opinion would compromise the participant's safety and/or compliance
             with the study procedures

          -  Participant has a known allergy, or history of anaphylaxis or other serious adverse
             reactions to vaccines or vaccine components (including any of the constituents of the
             study vaccine)

          -  For Cohort 3: Participant has received vaccination with seasonal influenza vaccine for
             the current influenza season in the northern hemisphere
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Vaccines &amp; Prevention B.V. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Vaccines &amp; Prevention B.V.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Optimal Research</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Optimal Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Optimal Research</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Optimal Research</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Optimal Research</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Optimal Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2018</study_first_submitted>
  <study_first_submitted_qc>April 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2018</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

